Uğur Şahin, BioNTech CEO (Kay Nietfeld/picture-alliance/dpa/AP Images)
February 4, 2022 01:46 PM EST
FDA+

BioN­Tech wait­ed to col­lect its $100M PRV un­til just be­fore Mod­er­na's Covid-19 vac­cine ap­proval

Zachary Brennan

Senior Editor

The FDA on Fri­day re­leased a new let­ter sent last week to BioN­Tech and Pfiz­er re­gard­ing their qui­et­ly held pri­or­i­ty re­view vouch­er. De­spite the fact …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times